TY - JOUR
TI - The Role of Metoprolol and Enalapril in the Prevention of
Doxorubicin-induced Cardiotoxicity in Lymphoma Patients
AU - Georgakopoulos, Peter
AU - Kyriakidis, Michael
AU - Perpinia, Anastasia
AU - and Karavidas, Apostolos
AU - Zimeras, Stelios
AU - Mamalis, Nikolaos and
AU - Kouvela, Marousa
AU - Charpidou, Andriani
JO - ANTICANCER RESEARCH
PY - 2019
VL - 39
TODO - 10
SP - 5703-5707
PB - INT INST ANTICANCER RESEARCH
SN - 0250-1291
TODO - 10.21873/anticanres.13769
TODO - Doxorubicin; cardiotoxicity; lymphoma
TODO - Background/Aim: Anthracyclines, such as doxorubicin, though widely used
in anticancer therapy, they are associated with cardiotoxic
side-effects. The aim of this trial was to investigate long-term
follow-up cardiotoxicity findings in patients treated with doxorubicin
and concomitant metoprolol or enalapril 10 years earlier. Patients and
Methods: Overall, 147 patients were randomized into the treatment arms.
A total of 125 patients treated with doxorubicin without evidence of
heart disease at the start of chemotherapy were analyzed. They were
followed-up for up to 10 years after treatment start. Results and
Conclusion: A total of 47 patients completed the follow-up and 21
patients died, none due to cardiotoxicity events. Clinical signs of
heart failure were not seen in any patients and no statistically
significant differences between baseline and 10-year findings were seen
for echocardiographic variables. No evidence of long-term cardiotoxicity
was seen and nor metoprolol or enalapril offered an additional benefit.
ER -